Professor
University of Ottawa Heart Institute
University of Ottawa Heart Insitute
Dr. Darryl Davis is a clinician-scientist and cardiac electrophysiologist at the University of Ottawa Heart Institute, where he leads a basic science laboratory focused on developing innovative therapies for atrial fibrillation. His research program integrates molecular discovery, translational science, and clinical application, with a particular emphasis on harnessing extracellular vesicles derived from the heart to prevent inflammation, fibrosis, and arrhythmias.
As Research Director for the Division of Cardiology, Dr. Davis has trained more than 100 highly qualified personnel and is committed to preparing the next generation of cardiovascular researchers. He has published widely in high-impact journals, pioneered novel preclinical models of atrial fibrillation and cardiac sarcoidosis, and has been recognized internationally for his work bridging laboratory discoveries with patient-centered outcomes.
Dr. Davis is also the Founder and CEO of Rhythm Biotherapeutics Inc., a biotech spinout from the University of Ottawa Heart Institute that is advancing the first heart-derived exosome therapeutic to clinical trials. His leadership in this area reflects his broader commitment to building bridges between basic research, clinical care, and population health—ensuring that promising molecular discoveries are translated into therapies that can improve outcomes for millions of patients worldwide.
In addition to his academic and entrepreneurial roles, Dr. Davis contributes to national and international cardiovascular research networks, including serving as Chair of the 2025 Annual Meeting of the American Association of Extracellular Vesicles. He is an active voice in shaping interdisciplinary collaborations, institutional strategies, and funding initiatives that support innovative science across the continuum of discovery to population health impact.
Disclosure information not submitted.
Thursday, October 23, 2025
3:15pm - 4:15pm ET